In Depth

Featured article

Pharma’s path to Net Zero: Targeting Scope 3 emissions

Also in this section

Profit vs inquiry: Clash of objectives in academic and commercial trials

CTO Europe 2023: A snapshot of challenges and opportunities in oncology

The future of cell and gene therapy manufacturing

VPAS is dead, long live VPAG

Q&A: European Pharmaceutical legislation: hindrance or help?

02/23/2024 23:27:04
  • Home | Pharma’s path to Net Zero: Targeting Scope 3 emissions
  • Editor's letter
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Project Updates
  • Dycem
  • In Depth
  • Pharma’s path to Net Zero: Targeting Scope 3 emissions
  • Profit vs inquiry: Clash of objectives in academic and commercial trials
  • CTO Europe 2023: A snapshot of challenges and opportunities in oncology
  • The future of cell and gene therapy manufacturing
  • VPAS is dead, long live VPAG
  • Q&A: European Pharmaceutical legislation: hindrance or help?
  • Natoli
  • Nipro
  • Yearbook
  • Yearbook contents
  • UK’s pharma regulatory scene reckons with changes in 2023
  • Pharma breakthroughs: 10 novel drug approvals that made headlines in 2023
  • Top themes of 2023: AI, precision medicine, virtual care, digital therapeutics
  • Humira biosimilars set the stage for long-awaited 2023 US launches
  • Inside the hunt for an Alzheimer’s disease vaccine
  • Pathbreakers: The journey of first generics
  • NASH drugs race to cross the finish line
  • Fighting AMR with a value and subscription model
  • Cancer treatment uncertainty: European nations struggle with drug shortages
  • Why are haemophilia gene therapies so expensive?
  • Top themes for the healthcare sector in 2024
  • Listings
  • Events
  • The top 100 most innovative companies in the US in 2023
  • Buyer's Guides
  • Next issue
12/18/2023 00:00:00